Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information ...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended authorization for the hemophilia A drug turoctocog alpha (NovoEight, NovoNordisk) yesterday for the ...
Bagsværd, Denmark, 16 October 2013 – Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics License Application (BLA) for recombinant coagulation ...
Today, Novo Nordisk announced new phase 3 interim data from its guardian(TM)2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight(R) (turoctocog alfa), the first new rFVIII ...
Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with Novoeight ® ...
Novo Nordisk today announced the company will launch Novoeight ® (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight ® offers purity, reliability, ...
"Establishing the stability of NovoEight ® up to 40°C is part of our commitment to helping people with haemophilia A to reduce the burden that this condition places on their lives," said Mads ...
Danish healthcare giant Novo Nordisk A/S (ADR) (NYSE: NVO) has developed NovoEight for the treatment and prevention of bleeding in patients with haemophilia A. NovoEight, which has already been ...
Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for ...
The active ingredient in NovoEight is turoctocog alfa, a B-domain truncated recombinant antihemophilic factor which is produced by third generation recombinant DNA technology Novo Nordisk has launched ...
A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40C.[1] The results were presented ...
The approval of 'Novoeight' marks an important step in offering a new alternative for people with haemophilia A," Novo Nordisk Corporate Vice President Business Area Gulf, India and Egypt, Mads Bo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results